Organisation paid for research Program year 2025 Source: CMS Open Payments

Arch Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$1,221,332

51 payments

Through program year 2025, Arch Clinical Trials is reported as receiving $1,221,332 in research payments, across 51 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$768,923	18
2024	Research	$354,609	12
2023	Research	$89,606	7
2022	Research	$5,422	3
2021	Research	$2,771	11

Breakdown

Who paid Research payments · program years 2021–2025

E.R. Squibb & Sons, L.L.C. $1,032,041 15 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $117,168 16 payments
ITI, Inc. $54,693 3 payments
Boehringer Ingelheim RCV GmbH & Co KG $14,373 15 payments
Indivior Inc. $2,708 1 payment
AbbVie, Inc. $349 1 payment

Studies the money was for Research payments · program years 2021–2025

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $461,285 3 payments
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $286,476 1 payment
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $178,704 1 payment
Connex-3 $64,213 18 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia $54,693 3 payments
Connex 3 $39,986 6 payments
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $35,739 3 payments
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder $22,483 1 payment
Connex-X $16,937 3 payments
Phase III OLE of KarXT in Adjuct Schiz (ARISE 2) - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $16,881 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.